Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01021891 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT01021891 is a Phase 1 study that has completed, run by Mannkind Corporation. The registered enrollment target is 39 participants.
The verdict
NCT01021891, a Phase 1 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
Trial will include 40 subjects and consists of 3 visits: Screening, Treatment and Follow up. A euglycemic clamp procedure and Technosphere®/Insulin (T/I) administration will occur at Visit 2 for both COPD and non COPD subjects.
Interventions
- DRUG Technosphere®/Insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01021891
The ClinicalTrials.gov registry entry for NCT01021891 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Technosphere®/Insulin is the first listed.
NCT01021891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01021891 about?
NCT01021891 is a clinical study titled "A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)". Trial will include 40 subjects and consists of 3 visits: Screening, Treatment and Follow up. A euglycemic clamp procedure and Technosphere®/Insulin (T/I) administration will occur at Visit 2 for both COPD and non COPD subjects.
What is the current status of trial NCT01021891?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2006-07. Estimated completion is 2008-11.
What interventions are being tested in trial NCT01021891?
The interventions under investigation include: Technosphere®/Insulin (DRUG).
Who is sponsoring clinical trial NCT01021891?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.